Recombinant human IL2 for the treatment of kidney cancer cells, a first monoclonal antibody for malignant B-cell tumors, the first DC-based cancer vaccine for the treatment of prostate cancer, cell therapy developed for the chimeric antigen receptor (CAR) for B-cell lymphoma, and programmed death ligand1 (PD-L1) immune checkpoint inhibitors for melanoma are examples of immunotherapies approved for the treatment of cancer over the past three decades [110]. This evidence concerns the gene CD274 and cancer.